Histone Deacetylase (HDAC) Inhibitors Market Growth Outlook From $1.42 Billion In 2026 To $1.89 Billion By 2030

Global Histone Deacetylase (HDAC) Inhibitors Market

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Histone Deacetylase (HDAC) Inhibitors Market Size, Value And Growth Trajectory Through 2030

The histone deacetylase (hdac) inhibitors market size has experienced robust growth in recent years. It is anticipated to expand from $1.32 billion in 2025 to $1.42 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.5%. This historical expansion was fueled by increasing oncology drug research activity, a rising understanding of epigenetic mechanisms, the proliferation of clinical trial programs, growing pharmaceutical R&D investments, and the accessibility of advanced molecular screening tools.

The histone deacetylase (hdac) inhibitors market is projected for significant expansion over the coming years. This market is set to reach $1.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. Factors contributing to this anticipated growth include a greater uptake of personalized cancer treatments, increased funding for epigenetic drug innovation, broader neurology-related hdac research, a heightened need for targeted medicines, and more regulatory approvals for new hdac inhibitors. Key trends anticipated during this period encompass a stronger emphasis on targeted epigenetic therapies, the accelerated development of selective hdac inhibitors, a wider application of combination oncology treatments, the expansion of precision medicine drug development pipelines, and a greater focus on biomarker-driven drug discovery.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=68817757&type=smp&name=Histone%20Deacetylase%20%28HDAC%29%20Inhibitors%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Histone Deacetylase (HDAC) Inhibitors Market Growth Factors: What’s Supporting Expansion?

The anticipated expansion of the histone deacetylase (HDAC) inhibitors market is primarily driven by the increasing prevalence of neurodegenerative conditions. These conditions involve the gradual deterioration and demise of neurons within the brain and spinal cord, resulting in impairments in cognitive and motor functions. Noteworthy examples include Alzheimer’s, which is distinguished by memory loss and a decline in cognitive abilities, stemming from the presence of amyloid plaques and tau tangles. Various elements contribute to the increasing occurrence of neurodegenerative disorders, including advanced age, extended lifespans, genetic predispositions, and environmental influences. Research is underway on histone deacetylase (HDAC) inhibitors as prospective therapeutic options for neurodegenerative disorders, given their capacity to regulate gene expression and offer neuroprotective benefits. A relevant example comes from August 2024, where the Centers for Disease Control and Prevention, a federal agency in the United States, reported an estimated 6.7 million older adults presently affected by Alzheimer’s disease in the United States. This figure is projected to climb to almost 14 million by 2060. Consequently, the growing occurrence of neurodegenerative conditions is a key factor propelling the expansion of the histone deacetylase (HDAC) inhibitors market.

Histone Deacetylase (HDAC) Inhibitors Market Segmentation: How Does The Market Break Down By Category?

The histone deacetylase (hdac) inhibitors market covered in this report is segmented –

1) By Class: Class I HDACs, Class II HDACs, Class III HDACs

2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors

3) By Application: Oncology, Neurology, Other Applications

4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8

2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10

3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7

Histone Deacetylase (HDAC) Inhibitors Market Trends Shaping Long-Term Demand

Companies prominently involved in the histone deacetylase (HDAC) inhibitors market are concentrating on devising innovative solutions, such as HDAC inhibitors for cancer treatment, to boost effectiveness and lessen adverse reactions. Histone deacetylase (HDAC) inhibitors constitute a category of pharmaceutical compounds employed in managing cancer. Their mechanism involves impeding the action of HDAC enzymes, which typically divest acetyl groups from histone proteins. This hindrance leads to elevated acetylation of histones, thereby altering chromatin structure and influencing gene expression. For example, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based entity focused on developing leading-edge cancer therapies, obtained New HDAC Inhibitor Patents for Cancer Treatment from the U.S. Patent and Trademark Office. These advanced inhibitors are precisely engineered to target particular HDAC enzymes linked to cancer progression, with the goal of disrupting irregular gene expression patterns that foster tumor expansion and metastasis. The patented agents display enhanced strength and specificity, thereby minimizing unintended effects and improving patient safety profiles during treatment.

Histone Deacetylase (HDAC) Inhibitors Market Competitive Overview And Top Companies

Major companies operating in the histone deacetylase (hdac) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.

View The Full Histone Deacetylase (HDAC) Inhibitors Market Report:

https://thebusinessresearchcompany.com/report/histone-deacetylase-hdac-inhibitors-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Histone Deacetylase (HDAC) Inhibitors Market Top Region By Revenue And Market Share

North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (hdac) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model